Subbian Ananth Karumanchi

Subbian Ananth Karumanchi

Auto-generated profile, based on publicly available information

Subbian Ananth Karumanchi

Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2019 in Nature Reviews Nephrology
Verified
Journal Article
Closed access
PDF file
EPElizabeth A. Phipps
Elizabeth A. Phipps
RTRavi Thadhani
Ravi Thadhani
TBThomas Benzing
Thomas Benzing
SKS. Ananth Karumanchi
S. Ananth Karumanchi

21 June 2011 in Circulation
Verified
Journal Article
Closed access
PDF file
CPCamille E. Powe
Camille E. Powe
RLRichard J. Levine
Richard J. Levine
SKS. Ananth Karumanchi
S. Ananth Karumanchi

1 February 2022 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Open access
SRSarosh Rana
Sarosh Rana
SBSuzanne D. Burke
Suzanne D. Burke
SKS. Ananth Karumanchi
S. Ananth Karumanchi
Preeclampsia is a devastating medical complication of pregnancy that can lead to significant maternal and fetal morbidity and mortality. It is currently believed that there is abnormal placentation in as early as the first trimester in women destined to develop preeclampsia. Although the etiology of the abnormal placentation is being debated, numerous epidemiologic and experimental studies suggest that imbalances in circulating angiogenic factors released from the placenta are responsible for the maternal signs and symptoms of preeclampsia. In particular, circulating levels of soluble fms-like tyrosine kinase 1, an antiangiogenic factor, are markedly increased in women with preeclampsia, whereas free levels of its ligand, placental, growth factor are markedly diminished. Alterations in these angiogenic factors precede the onset of clinical signs of preeclampsia and correlate with disease severity. Recently, the availability of automated assays for the measurement of angiogenic biomarkers in the plasma, serum, and urine has helped investigators worldwide to demonstrate a key role for these factors in the clinical diagnosis and prediction of preeclampsia. Numerous studies have reported that circulating angiogenic biomarkers have a very high negative predictive value to rule out clinical disease among women with suspected preeclampsia. These blood-based biomarkers have provided a valuable tool to clinicians to accelerate the time to clinical diagnosis and minimize maternal adverse outcomes in women with preeclampsia. Angiogenic biomarkers have also been useful to elucidate the pathogenesis of related disorders of abnormal placentation such as intrauterine growth restriction, intrauterine fetal death, twin-to-twin transfusion syndrome, and fetal hydrops. In summary, the discovery and characterization of angiogenic proteins of placental origin have provided clinicians a noninvasive blood-based tool to monitor placental function and health and for early detection of disorders of placentation. Uncovering the mechanisms of altered angiogenic factors in preeclampsia and related disorders of placentation may provide insights into novel preventive and therapeutic options.

1 November 2005 in Hypertension
Verified
Journal Article
Open access
PDF file
CLChun Lam
Chun Lam
KLKee-Hak Lim
Kee-Hak Lim
SKS. Ananth Karumanchi
S. Ananth Karumanchi
Preeclampsia is a major cause of maternal, fetal, and neonatal mortality worldwide. Although the etiology of preeclampsia is still unclear, recent studies suggest that its major phenotypes, high blood pressure and proteinuria, are due in part to excess circulating soluble fms-like tyrosine kinase-1 concentrations. Soluble fms-like tyrosine kinase-1 is an endogenous antiangiogenic protein that is made by the placenta and acts by neutralizing the proangiogenic proteins vascular endothelial growth factor and placental growth factor. High serum soluble fms-like tyrosine kinase-1 and low serum free placental growth factor and free vascular endothelial growth factor have been observed in preeclampsia. Abnormalities in these circulating angiogenic proteins are not only present during clinical preeclampsia but also antedate clinical symptoms by several weeks. Therefore, this raises the possibility of measuring circulating angiogenic proteins in the blood and the urine as a diagnostic and screening tool for preeclampsia. The availability of a test to predict preeclampsia would be a powerful tool in preventing preeclampsia-induced mortality, especially in developing nations, where high-risk specialists are limited. This review will summarize our current understanding of the role of circulating angiogenic proteins in the pathogenesis and clinical diagnosis/prediction of preeclampsia.

5 January 2005 in JAMA
Verified
Journal Article
Open access
PDF file
RLRichard J. Levine
Richard J. Levine
RTRavi Thadhani
Ravi Thadhani
CQCong Qian
Cong Qian
CLChun Lam
Chun Lam
KLKee-Hak Lim
Kee-Hak Lim
SKS. Ananth Karumanchi
S. Ananth Karumanchi
Preeclampsia is a common hypertensive disorder of pregnancy characterized by systemic endothelial dysfunction and diagnosed by the appearance of hypertension and proteinuria.1,2 For this reason, it is recommended that women undergo blood pressure and urinary protein screening at each prenatal visit throughout gestation.3 Potentially life-threatening complications of preeclampsia include seizures, cerebral hemorrhage, disseminated intravascular coagulation, and renal failure; and the time between the first detection of hypertension and proteinuria and the subsequent development of these complications can be extremely short.3,4 The only known cure for preeclampsia is delivery of the placenta. If maternal signs develop before the fetus is mature, the risk of neonatal morbidity and mortality due to premature delivery is markedly increased.

1 June 2005 in Kidney International
Verified
Journal Article
Closed access
SKS. Ananth Karumanchi
S. Ananth Karumanchi
SMSharon E. Maynard
Sharon E. Maynard
ISIsaac E. Stillman
Isaac E. Stillman
FEFranklin H. Epstein
Franklin H. Epstein
VSVikas P. Sukhatme
Vikas P. Sukhatme